Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 102 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2016, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 9, 3 and 1 respectively for Post-Polycythemia Vera Myelofibrosis (PPV-MF).

Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview 7
Therapeutics Development 8
Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview 8
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics under Development by Companies 9
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Products under Development by Companies 13
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development 14
Celgene Corporation 14
F. Hoffmann-La Roche Ltd. 15
Gilead Sciences, Inc. 16
Incyte Corporation 17
Italfarmaco S.p.A. 18
JW Pharmaceutical Corporation 19
MedImmune, LLC 20
MEI Pharma, Inc. 21
Nippon Shinyaku Co., Ltd. 22
Novartis AG 23
Pfizer Inc. 24
Promedior, Inc. 25
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
buparlisib hydrochloride - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
CWP-291 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
durvalumab - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
givinostat - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
glasdegib - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
idelalisib - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
itacitinib adipate - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
LCL-161 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
momelotinib dihydrochloride - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
NS-018 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
pomalidomide - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
pracinostat - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
PRM-151 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
vismodegib - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects 97
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products 98
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones 99
Featured News & Press Releases 99
Dec 10, 2015: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting 99
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102

List of Tables

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Celgene Corporation, H2 2016 14
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 15
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Gilead Sciences, Inc., H2 2016 16
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corporation, H2 2016 17
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco S.p.A., H2 2016 18
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by JW Pharmaceutical Corporation, H2 2016 19
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MedImmune, LLC, H2 2016 20
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MEI Pharma, Inc., H2 2016 21
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 22
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, H2 2016 23
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Pfizer Inc., H2 2016 24
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Promedior, Inc., H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, H2 2016 97
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H2 2016 98